Sharon M Moe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8886558/publications.pdf

Version: 2024-02-01

237 papers	16,975 citations	17440 63 h-index	15732 125 g-index
240 all docs	240 docs citations	240 times ranked	11084 citing authors

#	Article	IF	Citations
1	Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2006, 69, 1945-1953.	5.2	1,586
2	Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal of Medicine, 2004, 350, 1516-1525.	27.0	1,023
3	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. New England Journal of Medicine, 2012, 367, 2482-2494.	27.0	805
4	Executive summary of the 2017 KDIGO Chronic KidneyÂDiseaseâ€“Mineral and Bone Disorder (CKD-MBD) Guideline Update: whatâ€™s changed and why it matters. Kidney International, 2017, 92, 26-36.	5.2	698
5	Mechanisms of Vascular Calcification in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 213-216.	6.1	443
6	Pathophysiology of Vascular Calcification in Chronic Kidney Disease. Circulation Research, 2004, 95, 560-567.	4.5	440
7	Vegetarian Compared with Meat Dietary Protein Source and Phosphorus Homeostasis in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 257-264.	4.5	440
8	Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney International, 2002, 61, 638-647.	5.2	387
9	Prevalence of Calcidiol Deficiency in CKD: A Cross-Sectional Study Across Latitudes in the United States. American Journal of Kidney Diseases, 2005, 45, 1026-1033.	1.9	346
10	Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney International, 2005, 67, 2295-2304.	5.2	321
11	Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease. Circulation, 2006, 114, 1083-1087.	1.6	302
12	Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney International, 2002, 62, 1724-1731.	5.2	297
13	Achieving NKF-K/DOQIâ„¢ bone metabolism and disease treatment goals with cinacalcet HCl. Kidney International, 2005, 67, 760-771.	5.2	290
14	Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney International, 2003, 63, 1003-1011.	5.2	289
15	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. Circulation, 2015, 132, 27-39.	1.6	259
16	Disorders Involving Calcium, Phosphorus, and Magnesium. Primary Care - Clinics in Office Practice, 2008, 35, 215-237.	1.6	249
17	Chronic Kidney Diseaseâ€“Mineral-Bone Disorder: A New Paradigm. Advances in Chronic Kidney Disease, 2007, 14, 3-12.	1.4	228
18	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Diseaseâ€“Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Annals of Internal Medicine, 2018, 168, 422.	3.9	228

#	Article	IF	Citations
19	Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. American Journal of Kidney Diseases, 2016, 67, 559-566.	1.9	218
20	The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney International, 2003, 63, 248-254.	5.2	216
21	Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. JAMA - Journal of the American Medical Association, 2017, 317, 156.	7.4	213
22	Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. American Journal of Kidney Diseases, 2001, 37, 1267-1276.	1.9	210
23	Oral calcium carbonate affects calcium but not phosphorus balance in stage 3â€“4 chronic kidney disease. Kidney International, 2013, 83, 959-966.	5.2	205
24	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1466-1475.	6.1	163
25	High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrology Dialysis Transplantation, 2006, 21, 3435-3442.	0.7	159
26	Natural history of vascular calcification in dialysis and transplant patients. Nephrology Dialysis Transplantation, 2004, 19, 2387-2393.	0.7	150
27	Vascular Calcification: Pathophysiology and Risk Factors. Current Hypertension Reports, 2012, 14, 228-237.	3.5	150
28	Annexin-Mediated Matrix Vesicle Calcification in Vascular Smooth Muscle Cells. Journal of Bone and Mineral Research, 2008, 23, 1798-1805.	2.8	147
29	Assessment of vascular calcification in ESRD patients using spiral CT. Nephrology Dialysis Transplantation, 2003, 18, 1152-1158.	0.7	145
30	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 898-905.	4.5	144
31	Arterial calcification in diabetes. Current Diabetes Reports, 2003, 3, 28-32.	4.2	142
32	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. Journal of the American Society of Nephrology: JASN, 2018, 29, 2015-2027.	6.1	140
33	A rat model of chronic kidney disease-mineral bone disorder. Kidney International, 2009, 75, 176-184.	5.2	136
34	Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrology Dialysis Transplantation, 2005, 20, 2186-2193.	0.7	135
35	Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. JAMA - Journal of the American Medical Association, 2017, 317, 146.	7.4	122
36	Reimbursement of Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1291-1298.	6.1	121

#	Article	IF	Citations
37	The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney International, 2006, 70, 1046-1053.	5.2	116
38	Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product. American Journal of Nephrology, 2003, 23, 369-379.	3.1	115
39	Review of the Effects of Omega-3 Supplementation in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 182-192.	4.5	115
40	Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. European Journal of Clinical Investigation, 2006, 36, 51-62.	3.4	114
41	Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients a pilot study. Nephrology Dialysis Transplantation, 2007, 22, 3561-3567.	0.7	110
42	Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD). PLoS ONE, 2013, 8, e64558.	2.5	106
43	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Journal of the American Heart Association, 2014, 3, e001363.	3.7	105
44	Direct Effects of Phosphate on Vascular Cell Function. Advances in Chronic Kidney Disease, 2011, 18, 105-112.	1.4	103
45	Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy. Journal of Bone and Mineral Research, 2015, 30, 499-509.	2.8	103
46	Inflammation and Vascular Calcification. Blood Purification, 2005, 23, 64-71.	1.8	102
47	The Case against Calcium-Based Phosphate Binders. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 697-703.	4.5	89
48	Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways. Kidney International, 2018, 93, 343-354.	5.2	88
49	Osteoporosis in end-state renal disease. Seminars in Nephrology, 1999, 19, 115-22.	1.6	85
50	Pathophysiology of Vascular Calcification. Current Osteoporosis Reports, 2015, 13, 372-380.	3.6	83
51	The pathophysiology of early-stage chronic kidney diseaseâ€“mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. Journal of Bone and Mineral Research, 2011, 26, 2672-2681.	2.8	82
52	Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients. American Journal of Nephrology, 2014, 39, 8-15.	3.1	77
53	Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease. American Journal of Nephrology, 2011, 34, 211-219.	3.1	76
54	The Effect of a Diet Containing 70% Protein from Plants on Mineral Metabolism and Musculoskeletal Health in Chronic Kidney Disease. American Journal of Nephrology, 2014, 40, 582-591.	3.1	76

#	Article	IF	Citations
55	Variation in Serum and Plasma PTH Levels in Second-Generation Assays in Hemodialysis Patients: A Cross-sectional Study. American Journal of Kidney Diseases, 2008, 51, 987-995.	1.9	75
56	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 791-799.	4.5	75
57	Vascular calcification in dialysis patients: Pathogenesis and consequences. American Journal of Kidney Diseases, 2003, 41, S96-S99.	1.9	73
58	Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. American Journal of Kidney Diseases, 2003, 42, 1253-1259.	1.9	73
59	A Comparison of Calcium to Zoledronic Acid for Improvement of Cortical Bone in an Animal Model of CKD. Journal of Bone and Mineral Research, 2014, 29, 902-910.	2.8	72
60	Fractures in Patients with CKD: Time for Action. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1929-1931.	4.5	72
61	Fish Consumption and Omega-3 Fatty Acid Status and Determinants in Long-Term Hemodialysis. American Journal of Kidney Diseases, 2006, 47, 1064-1071.	1.9	71
62	A Randomized Trial of Cholecalciferol versus Doxercalciferol for Lowering Parathyroid Hormone in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 299-306.	4.5	67
63	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4834-4844.	3.6	63
64	Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatric Nephrology, 2003, 18, 969-975.	1.7	62
65	Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. PLoS ONE, 2016, 11, e0159411.	2.5	62
66	Adipocyte induced arterial calcification is prevented with sodium thiosulfate. Biochemical and Biophysical Research Communications, 2014, 449, 151-156.	2.1	61
67	Improving Global Outcomes in Mineral and Bone Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S127-S130.	4.5	58
68	Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca P product and aggressive wound care. Clinical Nephrology, 2002, 58, 238-243.	0.7	56
69	Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. American Journal of Physiology - Renal Physiology, 2007, 292, F599-F606.	2.7	55
70	Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney International, 2013, 84, 886-894.	5.2	54
71	CKDâ€“Mineral and Bone Disorder: Core Curriculum 2011. American Journal of Kidney Diseases, 2011, 58, 1022-1036.	1.9	53
72	Klotho. Circulation, 2012, 125, 2181-2183.	1.6	52

#	Article	IF	Citations
73	Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. JCI Insight, 2019, 4, .	5.0	52
74	Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney International, 2010, 77, 436-442.	5.2	51
75	VITAMIN D IN HEALTH AND DISEASE: The Role of Vitamin D in Vascular Calcification in Chronic Kidney Disease. Seminars in Dialysis, 2005, 18, 307-314.	1.3	50
76	Association of Hepatitis C Virus Infection With Prevalence and Development of Kidney Disease. American Journal of Kidney Diseases, 2008, 51, 885-892.	1.9	50
77	Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 1527-1532.	6.1	49
78	Vascular calcification in chronic kidney disease. Seminars in Nephrology, 2004, 24, 61-68.	1.6	48
79	A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. American Journal of Kidney Diseases, 2001, 38, 792-802.	1.9	45
80	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology Dialysis Transplantation, 2012, 27, 2872-2879.	0.7	45
81	Renal Osteodystrophy or Kidney-Induced Osteoporosis?. Current Osteoporosis Reports, 2017, 15, 194-197.	3.6	44
82	Safety and Efficacy of Long-Term Treatment of Secondary Hyperparathyroidism by Low-Dose Intravenous Calcitriol. American Journal of Kidney Diseases, 1992, 19, 532-539.	1.9	40
83	Cortical Bone Mechanical Properties Are Altered in an Animal Model of Progressive Chronic Kidney Disease. PLoS ONE, 2014, 9, e99262.	2.5	40
84	Uremic encephalopathy. Clinical Nephrology, 1994, 42, 251-6.	0.7	40
85	R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrology Dialysis Transplantation, 2009, 24, 2371-2377.	0.7	38
86	Calcium Homeostasis in Health and in Kidney Disease. , 2016, 6, 1781-1800.		38
87	Kidney Histopathology and Prediction of Kidney Failure: A Retrospective Cohort Study. American Journal of Kidney Diseases, 2020, 76, 350-360.	1.9	38
88	Î²2-microglobulin induces MMP-1 but not TIMP-1 expression in human synovial fibroblasts. Kidney International, 2000, 57, 2023-2034.	5.2	37
89	Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporosis International, 2013, 24, 1471-1481.	3.1	37
90	Differential miRNA Expression in Cells and Matrix Vesicles in Vascular Smooth Muscle Cells from Rats with Kidney Disease. PLoS ONE, 2015, 10, e0131589.	2.5	37

#	Article	IF	Citations
91	Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease. American Journal of Nephrology, 2013, 37, 191-198.	3.1	35
92	Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease. Osteoporosis International, 2015, 26, 977-985.	3.1	35
93	Efficacy of sodium thiosulfate for the treatment for calciphylaxis. Clinical Nephrology, 2011, 75, 485-490.	0.7	35
94	Pathogenesis of Arrhythmias in a Model of CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 2812-2821.	6.1	34
95	Calcium as a cardiovascular toxin in CKD-MBD. Bone, 2017, 100, 94-99.	2.9	33
96	The Case for Routine Parathyroid Hormone Monitoring. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 313-318.	4.5	32
97	Comparing Mandated Health Care Reforms. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1535-1543.	4.5	31
98	Effect of Advanced Glycation Endâ€Products (AGE) Lowering Drug ALTâ€711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKDâ€MBD. Journal of Bone and Mineral Research, 2020, 35, 608-617.	2.8	31
99	Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney International, 2011, 80, 612-619.	5.2	30
100	Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E594-E604.	3.5	30
101	Maintenance of Bone Mass in Patients Receiving Dialytic Therapy. American Journal of Kidney Diseases, 1993, 22, 300-307.	1.9	29
102	RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC). American Journal of Physiology - Renal Physiology, 2010, 299, F674-F680.	2.7	29
103	Hepatitis C Increases the Risk of Progression of Chronic Kidney Disease in Patients with Glomerulonephritis. American Journal of Nephrology, 2010, 32, 311-316.	3.1	27
104	Time course of rapid bone loss and cortical porosity formation observed by longitudinal Î¼CT in a rat model of CKD. Bone, 2019, 125, 16-24.	2.9	27
105	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. Kidney International, 2020, 98, 1589-1604.	5.2	27
106	EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney International, 2021, 99, 1225-1233.	5.2	26
107	Uremic Vascular Calcification. Journal of Investigative Medicine, 2006, 54, 380-384.	1.6	24
108	Bone marrow fat is increased in chronic kidney disease by magnetic resonance spectroscopy. Osteoporosis International, 2015, 26, 1801-1807.	3.1	24

#	Article	IF	Citations
109	Twenty-Four-Hour Urine Phosphorus as a Biomarker of Dietary Phosphorus Intake and Absorption in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1002-1012.	4.5	24
110	Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract. , 2020, 30, 4-10.		24
111	Role of IL-1Î² and prostaglandins in Î²2-microglobulin-induced bone mineral dissolution. Kidney International, 1995, 47, 587-591.	5.2	23
112	Signal transduction of Î²2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts. Kidney International, 2002, 61, 414-424.	5.2	23
113	Management of Renal Osteodystrophy in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2004, 24, 209-216.	2.3	23
114	Clinical Manifestations and Pathogenesis of Dialysisâ€Related Amyloidosis. Seminars in Dialysis, 1996, 9, 360-368.	1.3	23
115	Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Bone, 2015, 77, 50-56.	2.9	23
116	Disorders of calcium, phosphorus, and magnesium. American Journal of Kidney Diseases, 2005, 45, 213-218.	1.9	22
117	Confusion on the Complexity of Calcium Balance. Seminars in Dialysis, 2010, 23, 492-497.	1.3	22
118	Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1128-1138.	4.5	21
119	Pilot Study of the Effects of High-Protein Meals During Hemodialysis on Intradialytic Hypotension in Patients Undergoing Maintenance Hemodialysis. , 2019, 29, 102-111.		21
120	Characterizing Dysgeusia in Hemodialysis Patients. Chemical Senses, 2019, 44, 165-171.	2.0	21
121	Prevalence and Persistence of Uremic Symptoms in Incident Dialysis Patients. Kidney360, 2020, 1, 86-92.	2.1	21
122	Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question. Current Opinion in Nephrology and Hypertension, 2011, 20, 354-359.	2.0	20
123	Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model. Nephrology Dialysis Transplantation, 2016, 32, gfw274.	0.7	20
124	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 539-546.	4.5	20
125	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. CKJ: Clinical Kidney Journal, 2020, 13, 75-84.	2.9	20
126	Raloxifene improves skeletal properties in an animalÂmodel of cystic chronic kidney disease. Kidney International, 2016, 89, 95-104.	5.2	19

#	Article	IF	Citations
127	Age and sex effects on FGF23-mediated response to mild phosphate challenge. Bone, 2021, 146, 115885.	2.9	19
128	Vascular calcification: Hardening of the evidence. Kidney International, 2006, 70, 1535-1537.	5.2	18
129	GDF11 induces kidney fibrosis, renal cell epithelial-to-mesenchymal transition, and kidney dysfunction and failure. Surgery, 2018, 164, 262-273.	1.9	18
130	Chronic kidney disease and peripheral nerve function in the Health, Aging and Body Composition Study. Nephrology Dialysis Transplantation, 2019, 34, 625-632.	0.7	18
131	Cardiovascular Functional Changes in Chronic Kidney Disease: Integrative Physiology, Pathophysiology and Applications of Cardiopulmonary Exercise Testing. Frontiers in Physiology, 2020, 11, 572355.	2.8	18
132	The Role of the Synovium and Cartilage in the Pathogenesis of Î²2â€Microglobulinâ€ƒAmyloidosis. Seminars in Dialysis, 2001, 14, 127-130.	1.3	17
133	Intestinal Phosphorus Absorption in Moderate CKD and Healthy Adults Determined Using a Radioisotopic Tracer. Journal of the American Society of Nephrology: JASN, 2021, 32, 2057-2069.	6.1	17
134	Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease. Nephrology Dialysis Transplantation, 2015, 31, gfv352.	0.7	16
135	Reference data and calculators for second-generation HR-pQCT measures of the radius and tibia at anatomically standardized regions in White adults. Osteoporosis International, 2022, 33, 791-806.	3.1	16
136	The treatment of steroid-induced bone loss in transplantation. Current Opinion in Nephrology and Hypertension, 1997, 6, 544-549.	2.0	15
137	Uremic vasculopathy. Seminars in Nephrology, 2004, 24, 413-416.	1.6	15
138	A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 1738-1746.	2.9	15
139	Calcification or Classification?. Journal of the American Society of Nephrology: JASN, 2005, 16, 293-295.	6.1	14
140	What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?. Current Opinion in Nephrology and Hypertension, 2013, 22, 651-655.	2.0	14
141	Influence of Dietary Protein on Glomerular Filtration Before and After Bariatric Surgery: A Cohort Study. American Journal of Kidney Diseases, 2014, 63, 598-603.	1.9	14
142	Effect of dietary phosphorus intake and age on intestinal phosphorus absorption efficiency and phosphorus balance in male rats. PLoS ONE, 2018, 13, e0207601.	2.5	14
143	Tester and testing procedure influence clinically determined gait speed. Gait and Posture, 2019, 74, 83-86.	1.4	14
144	Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cy/+ rats. Scientific Reports, 2019, 9, 7936.	3.3	14

#	Article	IF	Citations
145	Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Diseaseâ€“Mineral Bone Disorder. Journal of Bone and Mineral Research, 2020, 35, 333-342.	2.8	14
146	Plant-Based Diets, the Gut Microbiota, and Trimethylamine N-Oxide Production in Chronic Kidney Disease: Therapeutic Potential and Methodological Considerations. , 2021, 31, 121-131.		14
147	The cardiovascularâ€“dialysis nexus: the transition to dialysis is a treacherous time for the heart. European Heart Journal, 2021, 42, 1244-1253.	2.2	14
148	Î²2-Microglobulin increases the expression of vascular cell adhesion molecule on human synovial fibroblasts. Kidney International, 2001, 59, 1951-1959.	5.2	13
149	Management of Chronic Kidney Disease Mineral-Bone Disorder. Advances in Chronic Kidney Disease, 2007, 14, 44-53.	1.4	13
150	Review article: Chronic kidney diseaseâ€•mineral bone disorder: Have we got the assays right?. Nephrology, 2009, 14, 374-382.	1.6	13
151	The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. Journal of Human Hypertension, 2016, 30, 204-209.	2.2	13
152	Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease. Bone, 2021, 143, 115632.	2.9	13
153	The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. CKJ: Clinical Kidney Journal, 2022, 15, 136-144.	2.9	13
154	Identity and localization of advanced glycation end products on human Î²2-microglobulin using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Analytical Biochemistry, 2003, 314, 322-325.	2.4	12
155	Precision of Biomarkers to Define Chronic Inflammation in CKD. American Journal of Nephrology, 2008, 28, 808-812.	3.1	12
156	Rationale to reduce calcium intake in adult patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2018, 27, 251-257.	2.0	12
157	A microRNA Approach to Discriminate Cortical Low Bone Turnover in Renal Osteodystrophy. JBMR Plus, 2020, 4, e10353.	2.7	12
158	Vascular Calcification: The Three-Hit Model. Journal of the American Society of Nephrology: JASN, 2009, 20, 1162.2-1164.	6.1	11
159	Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease. Heart Rhythm, 2016, 13, 1105-1112.	0.7	11
160	Comparison of Risk Factors for Pediatric Kidney Stone Formation: The Effects of Sex. Frontiers in Pediatrics, 2019, 7, 32.	1.9	11
161	Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance. Life, 2020, 10, 32.	2.4	11
162	Current Issues in the Management of Secondary Hyperparathyroidism and Bone Disease. Peritoneal Dialysis International, 2001, 21, 241-246.	2.3	10

#	Article	IF	Citations
163	The KDIGO guideline on dialysate calcium and patient outcomes: need for hard evidence. Kidney International, 2011, 79, 478.	5.2	10
164	Adverse Mandibular Bone Effects Associated with Kidney Disease Are Only Partially Corrected with Bisphosphonate and/or Calcium Treatment. American Journal of Nephrology, 2013, 38, 458-464.	3.1	10
165	Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium. Bone, 2014, 67, 139-144.	2.9	10
166	Mobility Impairment in Patients New to Dialysis. American Journal of Nephrology, 2020, 51, 705-714.	3.1	10
167	Calcium Builds Strong Bones, and More Is Betterâ€"Correct? Well, Maybe Not. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1877-1883.	4.5	9
168	Rebuttal. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 321.	4.5	9
169	Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis. American Journal of Nephrology, 2019, 49, 125-132.	3.1	9
170	Voluntary Wheel Running Has Beneficial Effects in a Rat Model of CKD-Mineral Bone Disorder (CKD-MBD). Journal of the American Society of Nephrology: JASN, 2019, 30, 1898-1909.	6.1	9
171	Regulation of reactive oxygen species in the pathogenesis of matrix vesicles induced calcification of recipient vascular smooth muscle cells. Vascular Medicine, 2021, 26, 585-594.	1.5	9
172	Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360, 2022, 3, 307-316.	2.1	9
173	Vitamin D, Cardiovascular Disease, and Survival in Dialysis Patients. Journal of Bone and Mineral Research, 2007, 22, V95-V99.	2.8	8
174	Chronic kidney disease-mineral bone disorder (CKD-MBD). IBMS BoneKEy, 2010, 7, 447-457.	0.0	8
175	Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease. Osteoporosis International, 2018, 29, 2139-2146.	3.1	8
176	Increasing Nephrologist Awareness of Symptom Burden in Older Hospitalized End-Stage Renal Disease Patients. American Journal of Nephrology, 2020, 51, 11-16.	3.1	8
177	Calcimimetics Alter Periosteal and Perilacunar Bone Matrix Composition and Material Properties in Early Chronic Kidney Disease. Journal of Bone and Mineral Research, 2020, 37, 1297-1306.	2.8	8
178	Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease. American Journal of Nephrology, 2016, 43, 20-31.	3.1	7
179	A comparison between physicians and computer algorithms for form CMSâ€2728 data reporting. Hemodialysis International, 2017, 21, 117-124.	0.9	7
180	The impact of advanced glycation end products on bone properties in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 411-417.	2.0	7

#	Article	IF	Citations
181	Feeling gutted in chronic kidney disease (CKD): Gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis. Seminars in Dialysis, 2021, , .	1.3	7
182	Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease. Bone, 2022, 157, 116340.	2.9	7
183	Management of renal osteodystrophy in peritoneal dialysis patients. Peritoneal Dialysis International, 2004, 24, 209-16.	2.3	7
184	Management of Chronic Kidney Diseaseâ€“Mineral Bone Disorder. Advances in Chronic Kidney Disease, 2007, 14, 2.	1.4	6
185	Moving Beyond the Assumed: Improving Fistula Success Rates. Journal of the American Society of Nephrology: JASN, 2017, 28, 2827-2829.	6.1	6
186	Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone, 2019, 127, 419-426.	2.9	6
187	Spot Urine Samples to Estimate Na and K Intake in Patients With Chronic Kidney Disease and Healthy Adults: A Secondary Analysis From a Controlled Feeding Study. , 2021, 31, 602-610.		6
188	N-acetylcysteine (NAC), an anti-oxidant, does not improve bone mechanical properties in a rat model of progressive chronic kidney disease-mineral bone disorder. PLoS ONE, 2020, 15, e0230379.	2.5	6
189	Chronic Kidney Disease-Mineral Bone Disorder. , 2010, , 98-114.		5
190	Effects of treadmill running in a rat model of chronic kidney disease. Biochemistry and Biophysics Reports, 2018, 16, 19-23.	1.3	5
191	Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis. Nephrology Dialysis Transplantation, 2018, 34, 1924-1931.	0.7	5
192	Advancing medical technology innovation and clinical translation via a model of industry-enabled technical and educational support: Indiana Clinical and Translational Sciences Instituteâ€™s Medical Technology Advance Program. Journal of Clinical and Translational Science, 2021, 5, e79.	0.6	5
193	Predicting fracture healing with blood biomarkers: the potential to assess patient risk of fracture nonunion. Biomarkers, 2021, 26, 703-717.	1.9	5
194	Current issues in the management of secondary hyperparathyroidism and bone disease. Peritoneal Dialysis International, 2001, 21 Suppl 3, S241-6.	2.3	5
195	[Vascular calcification in end stage renal disease]. Clinical Calcium, 2002, 12, 1417-22.	0.2	5
196	Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD. Nephrology Dialysis Transplantation, 2022, 37, 1857-1867.	0.7	5
197	Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study. Osteoporosis International, 2019, 30, 1693-1698.	3.1	4
198	Adverse Effects of Autoclaved Diets on the Progression of Chronic Kidney Disease and Chronic Kidney Disease-Mineral Bone Disorder in Rats. American Journal of Nephrology, 2020, 51, 381-389.	3.1	4

#	Article	IF	Citations
199	Calciphylaxis or vascular oxalosis?. CKJ: Clinical Kidney Journal, 2021, 14, 435-438.	2.9	4
200	Chronic Kidney Disease-Mineral Bone Disorder: Definitions and Rationale for a Systemic Disorder. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 119-127.	0.8	3
201	Skeletal vascular perfusion is altered in chronic kidney disease. Bone Reports, 2018, 8, 215-220.	0.4	3
202	Skeletal and cardiovascular consequences of a positive calcium balance during hemodialysis. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 539-550.	0.9	3
203	Genetic Variants Associated With Mineral Metabolism Traits in Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3866-e3876.	3.6	3
204	Clinical, histopathologic and molecular features of idiopathic and diabetic nodular mesangial sclerosis in humans. Nephrology Dialysis Transplantation, 2021, 37, 72-84.	0.7	2
205	Skeletal muscle metabolic responses to physical activity are muscle type specific in a rat model of chronic kidney disease. Scientific Reports, 2021, 11, 9788.	3.3	2
206	High Moral Distress in Clinicians Involved in the Care of Undocumented Immigrants Needing Dialysis in the United States. Health Equity, 2021, 5, 484-492.	1.9	2
207	Assessment of 18 Fâ€NaF Positron Emission Tomography Imaging for Early Coronary Artery Calcification. FASEB Journal, 2015, 29, 638.5.	0.5	2
208	<scp>Nonâ€Additive</scp> Effects of Combined <scp>NOX1</scp>/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Diseaseâ€Mineral and Bone Disorder (<scp>CKDâ€MBD</scp>). JBMR Plus, 2022, 6, e10600.	2.7	2
209	Vasopressin for Post-kidney Transplant Hypotension. Kidney International Reports, 2022, 7, 1364-1376.	0.8	2
210	<scp>Postdialysis</scp> serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders. Hemodialysis International, 2022, 26, 255-263.	0.9	2
211	Initiation of Dialysis Is Associated With Impaired Cardiovascular Functional Capacity. Journal of the American Heart Association, 2022, 11, .	3.7	2
212	A coculture model of synoviocytes and bone for the evaluation of potential arthritis therapies. Journal of Pharmacological and Toxicological Methods, 1999, 41, 127-134.	0.7	1
213	Cinacalcet Hydrochloride. Drugs, 2005, 65, 282-283.	10.9	1
214	Children with chronic kidney disease: are they insured as adults?. Pediatric Nephrology, 2011, 26, 995-996.	1.7	1
215	ASN Presidential Address 2014: Moving Past Nephrologyâ€™s Midlife Crisis. Journal of the American Society of Nephrology: JASN, 2015, 26, 791-795.	6.1	1
216	Single-cell RNA sequencing of intramedullary canal tissue to improve methods for studying fracture repair biology. BioTechniques, 2021, 71, 431-438.	1.8	1

#	Article	IF	Citations
217	Chronic Kidney Disease-Mineral Bone Disorder. , 2011, , 2021-2058.		1
218	Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease. Bone Reports, 2022, 16, 101174.	0.4	1
219	Treatment of Chronic Kidney Disease-Mineral Bone Disorder and Vascular Complications. Therapeutic Apheresis and Dialysis, 2006, 10, S2-S15.	0.9	0
220	3318 Phosphorus Absorption in Healthy Adults and in Patients with Moderate Chronic Kidney Disease. Journal of Clinical and Translational Science, 2019, 3, 51-51.	0.6	0
221	Bone and Kidney. , 2019, , 375-386.		0
222	Mineral Bone Disorders in Chronic Kidney Disease. , 2019, , 145-161.e6.		0
223	Sudden cardiac death in patients undergoing dialysis: More than a single toxin. Heart Rhythm, 2019, 16, 318-319.	0.7	0
224	Renal osteodystrophy and chronic kidney diseaseâ€“mineral bone disorder. , 2020, , 1463-1487.		0
225	Using Spot Urine Samples to Estimate Sodium and Potassium intake in Healthy vs CKD Patients: Results from a Controlled Feeding Study. Current Developments in Nutrition, 2020, 4, nzaa067_049.	0.3	0
226	4438 Twenty-four-hour Urinary Sodium Excretion Estimated from a Spot Urine Sample May Be Used as an Indicator of Intake in CKD Patients. Journal of Clinical and Translational Science, 2020, 4, 40-41.	0.6	0
227	The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis. CardioRenal Medicine, 2021, 11, 174-183.	1.9	0
228	Omegaâ€3 PUFA plasma and red blood cell status in chronic hemodialysis patients. FASEB Journal, 2006, 20, A183.	0.5	0
229	Oral fish oil supplementation is efficacious and well tolerated in chronic hemodialysis patients: a pilot study. FASEB Journal, 2007, 21, A696.	0.5	0
230	Nephrolithiasis in the Wpk/+ Rats. FASEB Journal, 2010, 24, 1030.2.	0.5	0
231	Reducing parathyroid hormone is essential for correcting cortical bone deficiencies associated with chronic kidney disease. FASEB Journal, 2013, 27, 967.10.	0.5	0
232	Treating Bone Quality in Chronic Kidney Disease. FASEB Journal, 2015, 29, 702.1.	0.5	0
233	Disorders of Phosphorous Homeostasis in CKD. , 2006, , 13-28.		0
234	Title is missing!. , 2020, 15, e0230379.		0

#	Article	IF	Citations
235	Title is missing!. , 2020, 15, e0230379.		0
236	Title is missing!. , 2020, 15, e0230379.		0
237	Title is missing!. , 2020, 15, e0230379.		0